A PET/CT volumetric parameter predicts prognosis of non‑small cell lung cancer treated using preoperative chemoradiotherapy and surgery: A retrospective case series study

Katsui,Kuniaki; Ogata,Takeshi; Tada,Akihiro; Watanabe,Kenta; Yoshio,Kotaro; Kuroda,Masahiro; Kiura,Katsuyuki; Hiraki,Takao; Toyooka,Shinichi; Kanazawa,Susumu

doi:10.3892/mco.2021.2235

A PET/CT volumetric parameter predicts prognosis of non‑small cell lung cancer treated using preoperative chemoradiotherapy and surgery: A retrospective case series study

Authors:
- Kuniaki Katsui
- Takeshi Ogata
- Akihiro Tada
- Kenta Watanabe
- Kotaro Yoshio
- Masahiro Kuroda
- Katsuyuki Kiura
- Takao Hiraki
- Shinichi Toyooka
- Susumu Kanazawa
View Affiliations

Affiliations: Department of Proton Beam Therapy, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700‑8558, Japan, Department of Radiology, Iwakuni Clinical Center, Iwakuni, Yamaguchi 740‑8510, Japan, Department of Radiology, Okayama Diagnostic Imaging Center, Okayama 700‑0913, Japan, Department of Radiology, Okayama University Hospital, Okayama 700‑8558, Japan, Department of Radiological Technology, Graduate School of Health Sciences, Okayama University, Okayama 700‑8558, Japan, Department of Allergy and Respiratory Medicine, Okayama University Hospital, Okayama 700‑8558, Japan, Department of Radiology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700‑8558, Japan, Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700‑8558, Japan
Published online on: February 23, 2021 https://doi.org/10.3892/mco.2021.2235
Article Number: 73
Copyright: © Katsui et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The purpose of the present study was to clarify whether positron emission tomography/computed tomography (PET/CT) volumetric parameters were prognostic predictors of non‑small cell lung cancer (NSCLC) treatment in patients who had undergone preoperative concurrent chemoradiotherapy (CCRT) and surgery. In the present study, retrospectively surveyed the data of patients with NSCLC who underwent preoperative CCRT and surgery at Okayama University Hospital (Okayama, Japan) between April 2006 and March 2018. The maximum standardized uptake value (SUV_max) and volumetric parameters, including metabolic tumor volume (MTV) and total lesion glycolysis (TLG), were calculated using PET/CT and the percentage decrease (Δ) in each parameter value post‑CCRT. The SUV_max threshold for defining MTV was set at 2.5. Furthermore, the association between survival and PET parameter values was analyzed. A total of 52 patients were included in the present study. The median follow‑up period was 50.65 months. In univariate analysis, ΔTLG was identified to be a significant predictor of progression‑free survival (PFS; P=0.03). The 5‑year PFS rates were 48.6 and 76.6% for patients with low ΔTLG and high ΔTLG, respectively. High ΔTLG was indicative of a higher overall survival rate (P=0.08). The present results suggest that ΔTLG calculated using PET/CT is a prognostic predictor of NSCLC treated using preoperative CCRT and surgery, and may help physicians determine treatment strategies.

View Figures

View References

1	Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Yokoi T, Chiappori A, Lee KH, de Wit M, et al: Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med. 377:1919–1929. 2017.PubMed/NCBI View Article : Google Scholar
2	Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Kurata T, Chiappori A, Lee KH, de Wit M, et al: Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N Engl J Med. 379:2342–2350. 2018.PubMed/NCBI View Article : Google Scholar
3	Toyooka S, Kiura K, Takemoto M, Oto T, Takigawa N, Fujiwara T, Miyoshi S and Date H: Long-term outcome of induction chemoradiotherapy with docetaxel and cisplatin followed by surgery for non-small-cell lung cancer with mediastinal lymph node metastasis. Interact Cardiovasc Thorac Surg. 14:565–569. 2012.PubMed/NCBI View Article : Google Scholar
4	Albain KS, Swann RS, Rusch VW, Turrisi AT III, Shepherd FA, Smith C, Chen Y, Livingston RB, Feins RH, Gandara DR, et al: Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: A phase III randomised controlled trial. Lancet. 374:379–386. 2009.PubMed/NCBI View Article : Google Scholar
5	Na F, Wang J, Li C, Deng L, Xue J and Lu Y: Primary tumor standardized uptake value measured on F18-Fluorodeoxyglucose positron emission tomography is of prediction value for survival and local control in non-small-cell lung cancer receiving radiotherapy: Meta-analysis. J Thorac Oncol. 9:834–842. 2014.PubMed/NCBI View Article : Google Scholar
6	Liu J, Dong M, Sun X, Li W, Xing L and Yu J: Prognostic value of ¹⁸F-FDG PET/CT in surgical non-small cell lung cancer: A meta-analysis. PLoS One. 11(e0146195)2016.PubMed/NCBI View Article : Google Scholar
7	Nair VS, Krupitskaya Y and Gould MK: Positron emission tomography ¹⁸F-fluorodeoxyglucose uptake and prognosis in patients with surgically treated, stage I non-small cell lung cancer: A systematic review. J Thorac Oncol. 4:1473–1479. 2009.PubMed/NCBI View Article : Google Scholar
8	Im HJ, Bradshaw T, Solaiyappan M and Cho SY: Current methods to define metabolic tumor volume in positron emission tomography: Which one is better? Nucl Med Mol Imaging. 52:5–15. 2018.PubMed/NCBI View Article : Google Scholar
9	Park SY, Cho A, Yu WS, Lee CY, Lee JG, Kim DJ and Chung KY: Prognostic value of total lesion glycolysis by ¹⁸F-FDG PET/CT in surgically resected stage IA non-small cell lung cancer. J Nucl Med. 56:45–49. 2015.PubMed/NCBI View Article : Google Scholar
10	Shrestha S, Higuchi T, Shirai K, Tokue A, Shrestha S, Saitoh JI, Hirasawa H, Ohno T, Nakano T and Tsushima Y: Prognostic significance of semi-quantitative FDG-PET parameters in stage I non-small cell lung cancer treated with carbon-ion radiotherapy. Eur J Nucl Med Mol Imaging. 47:1220–1227. 2019.PubMed/NCBI View Article : Google Scholar
11	Satoh Y, Onishi H, Nambu A and Araki T: Volume-based parameters measured by using FDG PET/CT in patients with stage I NSCLC treated with stereotactic body radiation therapy: Prognostic value. Radiology. 270:275–281. 2014.PubMed/NCBI View Article : Google Scholar
12	Grootjans W, Usmanij EA, Oyen WJ, van der Heijden EH, Visser EP, Visvikis D, Hatt M, Bussink J and de Geus-Oei LF: Performance of automatic image segmentation algorithms for calculating total lesion glycolysis for early response monitoring in non-small cell lung cancer patients during concomitant chemoradiotherapy. Radiother Oncol. 119:473–479. 2016.PubMed/NCBI View Article : Google Scholar
13	Machtay M, Duan F, Siegel BA, Snyder BS, Gorelick JJ, Reddin JS, Munden R, Johnson DW, Wilf LH, DeNittis A, et al: Prediction of survival by [¹⁸F]fluorodeoxyglucose positron emission tomography in patients with locally advanced non-small-cell lung cancer undergoing definitive chemoradiation therapy: Results of the ACRIN 6668/RTOG 0235 trial. J Clin Oncol. 20:3823–3830. 2013.PubMed/NCBI View Article : Google Scholar
14	Salavati A, Duan F, Snyder BS, Wei B, Houshmand S, Khiewvan B, Opanowski A, Simone CB II, Siegel BA, Machtay M and Alavi A: Optimal FDG PET/CT volumetric parameters for risk stratification in patients with locally advanced non-small cell lung cancer: Results from the ACRIN 6668/RTOG 0235 trial. Eur J Nucl Med Mol Imaging. 44:1969–1983. 2017.PubMed/NCBI View Article : Google Scholar
15	Hyun SH, Choi JY, Kim K, Kim J, Shim YM, Um SW, Kim H, Lee KH and Kim BT: Volume-based parameters of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography improve outcome prediction in early-stage non-small cell lung cancer after surgical resection. Ann Surg. 257:364–370. 2013.PubMed/NCBI View Article : Google Scholar
16	Hyun SH, Ahn HK, Kim H, Ahn MJ, Park K, Ahn YC, Kim J, Shim YM and Choi JY: Volume-based assessment by (18)F-FDG PET/CT predicts survival in patients with stage III non-small-cell lung cancer. Eur J Nucl Med Mol Imaging. 41:50–58. 2014.PubMed/NCBI View Article : Google Scholar
17	Hyun SH, Ahn HK, Ahn MJ, Ahn YC, Kim J, Shim YM and Choi JY: Volume-based assessment with ¹⁸F-FDG PET/CT improves outcome prediction for patients with stage IIIa-N2 non-small cell lung cancer. AJR Am J Roentgenol. 205:623–628. 2015.PubMed/NCBI View Article : Google Scholar
18	Ogata T, Katsui K, Yoshio K, Ihara H, Katayama N, Soh J, Kuroda M, Kiura K, Maeda Y, Toyooka S and Kanazawa S: Dose-volume parameters predict radiation pneumonitis after surgery with induction concurrent chemoradiotherapy for non-small cell lung cancer. Acta Med Okayama. 72:507–513. 2018.PubMed/NCBI View Article : Google Scholar
19	Katsui K, Ogata T, Watanabe K, Katayama N, Kuroda M, Kiura K, Hiraki T, Maeda Y, Toyooka S and Kanazawa S: Radiation pneumonitis after definitive concurrent chemoradiotherapy with cisplatin/docetaxel for non-small cell lung cancer: Analysis of dose-volume parameters. Cancer Med. 9:4540–4549. 2020.PubMed/NCBI View Article : Google Scholar
20	Segawa Y, Kiura K, Takigawa N, Kamei H, Harita S, Hiraki S, Watanabe Y, Sugimoto K, Shibayama T, Yonei T, et al: Phase III trial comparing docetaxel and cisplatin combination chemotherapy with mitomycin, vindesine, and cisplatin combination chemotherapy with concurrent thoracic radiotherapy in locally advanced non-small-cell lung cancer: OLCSG 0007. J Clin Oncol. 28:3299–3306. 2010.PubMed/NCBI View Article : Google Scholar
21	Takigawa N, Kiura K, Hotta K, Hosokawa S, Nogami N, Aoe K, Gemba K, Fujiwara K, Harita S, Takemoto M, et al: A phase I study of S-1 with concurrent thoracic radiotherapy in elderly patients with localized advanced non-small cell lung cancer. Lung Cancer. 71:60–64. 2011.PubMed/NCBI View Article : Google Scholar
22	Im HJ, Pak K, Cheon GJ, Kang KW, Kim SJ, Kim IJ, Chung JK, Kim EE and Lee DS: Prognostic value of volumetric parameters of (18)F-FDG PET in non-small-cell lung cancer: A meta-analysis. Eur J Nucl Med Mol Imaging. 42:241–251. 2015.PubMed/NCBI View Article : Google Scholar
23	Huang W, Fan M, Liu B, Fu Z, Zhou T, Zhang Z, Gong H and Li B: Value of metabolic tumor volume on repeated ¹⁸F-FDG PET/CT for early prediction of survival in locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy. J Nucl Med. 55:1584–1590. 2014.PubMed/NCBI View Article : Google Scholar
24	Keyes JW Jr: SUV: Standard uptake or silly useless value? J Nucl Med. 36:1836–1839. 1995.PubMed/NCBI
25	Boellaard R, Krak NC, Hoekstra OS and Lammertsma AA: Effects of noise, image resolution, and ROI definition on the accuracy of standard uptake values: A simulation study. J Nucl Med. 45:1519–1527. 2004.PubMed/NCBI
26	Denis F, Lethrosne C, Pourel N, Molinier O, Pointreau Y, Domont J, Bourgeois H, Senellart H, Trémolières P, Lizée T, et al: Randomized trial comparing a web-mediated follow-up with routine surveillance in lung cancer patients. J Natl Cancer Inst. 109:2017.PubMed/NCBI View Article : Google Scholar
27	Wahl RL, Jacene H, Kasamon Y and Lodge MA: From RECIST to PERCIST: Evolving considerations for PET response criteria in solid tumors. J Nucl Med. 50 (Suppl 1):122S–150S. 2009.PubMed/NCBI View Article : Google Scholar